NDA 208151 · Alcon Labs INC
Isopto Atropine
Atropine Sulfate · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Aug 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Dec 1, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
414
74 Phase 3, 30 recruiting
FAERS reports
2,595
2,182 serious, 414 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 13, 2026.
Atropine Sulfate Ophthalmic Solution, 1% is indicated for: Atropine Sulfate Ophthalmic Solution, 1% is a muscarinic antagonist indicated for: Mydriasis ( 1.1 ) Cycloplegia ( 1.2 ) Penalization of the healthy eye in the treatment of amblyopia ( 1.3 ) 1.1 Mydriasis 1.2 Cycloplegia 1.3 Penalization of the healthy eye in the treatment of amblyopia
Mechanism: Atropine acts as a competitive antagonist of the parasympathetic (and sympathetic) acetylcholine muscarinic receptors. Topical atropine on the eye induces mydriasis by inhibiting contraction of the circular pupillary sphincter muscle normally stimulated by acetylcholine. This inhibition allows the countering radial pupillary dilator muscle to contract which results in dilation of the pupil. Additionally, atropine induces cycloplegia by paralysis of the ciliary muscle which controls accommodation while viewing objects.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ISOPTO ATROPINE · ATROPINE SULFATE 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2
Clinical trials
Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00400153 · 1,480 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Atrovent Respimat (20 mcg); COMBIVENT MDI (36/206 mcg) and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 180 sites in all
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01422304 · 1,198 participants · Start Oct 12, 2011 · Primary completion Sep 26, 2012
Drug: Sugammadex; neostigmine and glycopyrrolate or atropine and 2 more · For: Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee and 2 more
- Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02177253 · 1,118 participants · Start Oct 2002 · Primary completion Mar 2004
Drug: Ipratropium bromide / Salbutamol; Placebo Inhalation solution and 3 more · For: Pulmonary Disease, Chronic Obstructive
- A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible BronchoscopyPivotal-lookingStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT06376942 · 1,050 participants (planned) · Start Apr 24, 2024 · Primary completion Apr 25, 2025
Drug: Glycopyrronium; Ipratropium · For: Subjects Undergoing Flexible Bronchoscopy
Sites: Chandigarh, India
- Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) OutcomePivotal-lookingCompleted
Petter Andreas SteenAcademic, hospital or other
NCT00121524 · 904 participants · Start Jan 2003 · Primary completion May 2008
Drug: Epinephrine; Atropine and 1 more · For: Cardiac Arrest
Sites: Oslo, Norway
- The Safety and Efficacy of SYD-101 in Children With MyopiaPivotal-lookingCompleted
Sydnexis, Inc.Industry
NCT03918915 · 852 participants · Start Apr 24, 2019 · Primary completion May 2, 2024
Drug: SYD-101 0.01%; SYD-101 0.03% and 1 more · For: Nearsightedness; Near Sightedness; Near-sightedness
Sites: Irwindale, California; Pasadena, California; San Diego, California · 47 sites in all
- A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsPivotal-lookingActive, not recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06209320 · 777 participants (planned) · Start Mar 15, 2022 · Primary completion Mar 21, 2025
Drug: Lower dose atropine sulfate eye drops; Low dose atropine sulfate eye drops and 1 more · For: Myopia
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective315
- off label use214
- macular degeneration199
- nausea192
- pyrexia162
- diarrhoea150
- pain138
- malaise132
- headache129
- death124
- weight decreased120
- constipation117
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 55 |
| 2005 | 62 |
| 2006 | 50 |
| 2007 | 55 |
| 2008 | 73 |
| 2009 | 45 |
| 2010 | 75 |
| 2011 | 67 |
| 2012 | 71 |
| 2013 | 60 |
| 2014 | 68 |
| 2015 | 78 |
| 2016 | 117 |
| 2017 | 97 |
| 2018 | 125 |
| 2019 | 184 |
| 2020 | 164 |
| 2021 | 152 |
| 2022 | 230 |
| 2023 | 237 |
| 2024 | 236 |
| 2025 | 189 |
| 2026 | 104 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis.
Yellepeddi VK, Race JA, McFarland MM, et al. · Int J Clin Pharmacol Ther 2024 · Systematic Review, Meta-Analysis
- Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
Yam JC, Jiang Y, Tang SM, et al. · Ophthalmology 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
- Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.
Yam JC, Zhang XJ, Zhang Y, et al. · JAMA 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Myopia control strategies: A systematic review and meta-meta-analysis.
Zaabaar E, Asiamah R, Kyei S, et al. · Ophthalmic Physiol Opt 2025 · Systematic Review, Meta-Analysis
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Myopia prevention and control in children: a systematic review and network meta-analysis.
Zhang G, Jiang J, Qu C · Eye (Lond) 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.